세계의 항레트로바이러스 약물 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Anti-retroviral Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

US $ 3,920 ￦ 5,818,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730 ￦ 7,020,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430 ￦ 11,027,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

한글목차

세계의 항레트로바이러스 약물 시장은 크게 성장하고 있으며 2024년 356억 2,000만 달러에서 2033년에는 529억 8,000만 달러에 이를 전망입니다. 2025-2033년 연평균 복합 성장률(CAGR)은 4.51%로 성장할 것으로 예측됩니다.

세계의 항레트로바이러스 약물 시장은 HIV/AIDS의 유행과 병용 요법 및 장시간 작용형 제제의 진보에 의해 꾸준히 성장할 것으로 보입니다. 인테그라제 억제제 및 진입 억제제를 포함한 새로운 약물 클래스별로 바이러스 억제와 환자의 어드히어런스를 향상시키고 있습니다. 향후 개발은 주사와 이식 가능한 전달 시스템, 그리고 치유의 가능성이 있는 바이러스 저장고를 표적으로 한 전략 등을 주목할 예정입니다.

또한 세계 건강 이니셔티브를 통한 중저소득 국가의 치료 접근성 확대로 환자의 적용 범위가 확대되고 있습니다. 디지털 어드히어런스 모니터링과 텔레헬스의 통합으로 치료 성적이 향상되었습니다. 규제 당국의 승인과 특허 만료는 시장 역학에 영향을 미치고 있습니다. HIV 치료가 진보함에 따라, 항레트로바이러스 약물 시장은 혁신을 계속할 것이며, 더욱 안전하고 효과적이며 사용하기 쉬운 치료법을 계속 제공할 것입니다.

목차

제1장 서문

제2장 주요 요약

• 시장의 하이라이트
• 세계 시장 현황

제3장 항레트로바이러스 약물 : 산업 분석

• 서문 : 시장 역학
• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 업계 동향
• Porter's Five Forces 분석
• 시장 매력 분석

제4장 밸류체인 분석

• 밸류체인 분석
• 원재료 분석
  • 원재료 리스트
  • 원재료 제조업체 리스트
  • 주요 원재료의 가격 동향
• 잠재적 구매자 목록
• 마케팅 채널
  • 직접 마케팅
  • 간접 마케팅
  • 마케팅 채널 발전 동향

제5장 세계의 항레트로바이러스 약물 시장 분석 : 제품별

• 개요 : 제품별
• 과거 및 예측 데이터 분석 : 제품별
• 프로테아제 억제제
• 인테그라제 억제제
• 멀티클래스 콤비네이션 제품
• 뉴클레오시드 역전사효소 억제제(NRTIS)
• 비뉴클레오시드계 역전사효소 억제제(NRTIS)
• 기타 약제 클래스별

제6장 세계의 항레트로바이러스 약물 시장 분석 : 유형별

• 개요 : 유형별
• 과거 및 예측 데이터 분석 : 유형별
• 브랜드
• 제네릭

제7장 세계의 항레트로바이러스 약물 시장 분석 : 연령층별

• 개요 : 연령층별
• 과거 및 예측 데이터 분석 : 연령층별
• 성인
• 소아
• 노년

제8장 세계의 항레트로바이러스 약물 시장 분석 : 유통 채널별

• 개요 : 유통 채널별
• 과거 및 예측 데이터 분석 : 유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국

제9장 세계의 항레트로바이러스 약물 시장 분석 : 지역별

• 지역별 전망
• 서문
• 북미의 매출 분석
  • 개요, 분석 및 예측
  • 북미 : 부문별
  • 북미 국가별
  • 미국
  • 캐나다
  • 멕시코
• 유럽의 매출 분석
  • 개요, 분석 및 예측
  • 유럽 : 부문별
  • 유럽 국가별
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양의 매출 분석
  • 개요, 분석 및 예측
  • 아시아태평양 : 부문별
  • 아시아태평양 국가별
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주
  • 동남아시아
  • 기타 아시아태평양
• 라틴아메리카의 매출 분석
  • 개요, 분석 및 예측
  • 라틴아메리카 : 부문별
  • 라틴아메리카 국가별
  • 브라질
  • 아르헨티나
  • 페루
  • 칠레
  • 기타 라틴아메리카
• 중동 및 아프리카의 매출 분석
  • 개요, 분석 및 예측
  • 중동 및 아프리카 : 부문별
  • 중동 및 아프리카 국가별 일람
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 남아프리카
  • 기타 중동 및 아프리카

제10장 항레트로바이러스 약물 기업 경쟁 구도

• 항레트로바이러스 약물 시장 경쟁
• 제휴, 협력 및 합의
• 합병 및 인수
• 신제품 출시
• 기타 개발

제11장 기업 프로파일

• 주요 기업의 시장 점유율 분석
• 시장 집중도
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Cipla
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co. Inc.
• Pfizer Inc.
• Viatris Inc

AJY

영문 목차

영문목차

Global Anti-retroviral Drugs Market is poised to witness substantial growth, reaching a value of USD 52.98 Billion by the year 2033, up from USD 35.62 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 4.51% between 2025 and 2033.

The global anti-retroviral drugs market is set for steady growth driven by the ongoing HIV/AIDS epidemic and advancements in combination therapies and long-acting formulations. Novel drug classes, including integrase inhibitors and entry inhibitors, are improving viral suppression and patient adherence. Future developments will focus on injectable and implantable delivery systems, as well as strategies targeting viral reservoirs for potential cure.

Additionally, expanding access to treatment in low- and middle-income countries through global health initiatives is broadening patient coverage. The integration of digital adherence monitoring and telehealth is enhancing treatment outcomes. Regulatory approvals and patent expirations are influencing market dynamics. As HIV care advances, the anti-retroviral drugs market will continue to innovate, delivering safer, more effective, and accessible therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Anti-retroviral Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Protease Inhibitors
• Integrase Inhibitors
• Multi-Class Combination Products
• Nucleoside Reverse Transcriptase Inhibitors (NRTIS)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIS)
• Other Drug Classes

By Type

• Branded
• Generic

By Age Group

• Adult
• Pediatric
• Geriatric

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• List of Companies Profiled in the report
• AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Viatris Inc.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ANTI-RETROVIRAL DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Type
  • 3.7.3 Market Attractiveness Analysis By Age Group
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data Analysis By Product
• 5.3. Protease Inhibitors Historic and Forecast Sales By Regions
• 5.4. Integrase Inhibitors Historic and Forecast Sales By Regions
• 5.5. Multi-Class Combination Products Historic and Forecast Sales By Regions
• 5.6. Nucleoside Reverse Transcriptase Inhibitors (NRTIS) Historic and Forecast Sales By Regions
• 5.7. Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIS) Historic and Forecast Sales By Regions
• 5.8. Other Drug Classes Historic and Forecast Sales By Regions

6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET ANALYSIS BY TYPE

• 6.1. Overview By Type
• 6.2. Historical and Forecast Data Analysis By Type
• 6.3. Branded Historic and Forecast Sales By Regions
• 6.4. Generic Historic and Forecast Sales By Regions

7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET ANALYSIS BY AGE GROUP

• 7.1. Overview By Age Group
• 7.2. Historical and Forecast Data Analysis By Age Group
• 7.3. Adult Historic and Forecast Sales By Regions
• 7.4. Pediatric Historic and Forecast Sales By Regions
• 7.5. Geriatric Historic and Forecast Sales By Regions

8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1. Overview By Distribution Channel
• 8.2. Historical and Forecast Data Analysis By Distribution Channel
• 8.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 8.4. Retail Pharmacy Historic and Forecast Sales By Regions
• 8.5. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ANTI-RETROVIRAL DRUGS COMPANIES

• 10.1. Anti-retroviral Drugs Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF ANTI-RETROVIRAL DRUGS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. AbbVie Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Boehringer Ingelheim International GmbH
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Bristol-Myers Squibb Company
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Cipla
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. F. Hoffmann-La Roche Ltd.
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Gilead Sciences Inc.
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. GlaxoSmithKline Plc
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Johnson & Johnson
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Merck & Co. Inc.
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Pfizer Inc.
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Viatris Inc
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

관련자료